Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tilsotolimod with Nivolumab and Ipilimumab in Solid Tumors
NCT03865082Phase 2Active, not recruiting
- Sponsor
- Aceragen, Inc.
- Start
- Oct 2019
- Primary completion
- Mar 2022
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of tilsotolimod in colorectal cancer (CRC), sponsored by Aceragen, Inc.. Started Oct 2019; status: active, not recruiting.
02
Drugs
tilsotolimod
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03865082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03865082.